Edgewise Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-57.33Mn |
Net Profit Margins | -Inf% |
Edgewise Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Edgewise Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Edgewise Therapeutics, Inc. Common Stock’s net profit fell -58.73% since last year same period to $-57.33Mn in the Q2 2026. On a quarterly growth basis, Edgewise Therapeutics, Inc. Common Stock has generated -16.96% fall in its net profits since last 3-months.
Edgewise Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Edgewise Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Current Year | -0.48 |
Edgewise Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a 0% jump from last quarter’s estimates.
Edgewise Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.48.
Key Ratios
Earning Per Share (EPS) | -0.53 |
Edgewise Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -55.88% since last year same period to -0.53 in the Q2 2026. This indicates that the Edgewise Therapeutics, Inc. Common Stock has generated -55.88% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-07 | -0.48 | -0.46 | 4.17% |
2026-08-06 | -0.48 | -0.53 | -10.42% |
